Literature DB >> 7129207

Plasma prednisolone levels during intravenous therapy in acute colitis.

L M Berghouse, P R Elliott, J E Lennard-Jones, J English, V Marks.   

Abstract

Maximum plasma levels in six acute colitics were about three times greater after an intravenous bolus of 20 mg prednisolone than the mean level achieved during infusion of the same dose (p<0.001) over eight hours; the level during infusion was about twice as great as the maximum recorded previously after a single 40 mg oral dose of prednisolone. These findings favour the use of intravenous administration in severe acute colitis. No difference was found between plasma levels of patients and six normal subjects after the intravenous bolus.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7129207      PMCID: PMC1419807          DOI: 10.1136/gut.23.11.980

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  5 in total

1.  Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone.

Authors:  J H BARON; A M CONNELL; T G KANAGHINIS; J E LENNARD-JONES; A F JONES
Journal:  Br Med J       Date:  1962-08-18

2.  A controlled evaluation of intravenous adrenocorticotropic hormone and hydrocortisone in the treatment of acute colitis.

Authors:  H P Kaplan; B Portnoy; H J Binder; T Amatruda; H Spiro
Journal:  Gastroenterology       Date:  1975-07       Impact factor: 22.682

3.  A radioimmunoassay method for prednisolone: comparison with the competitive protein binding method.

Authors:  J Chakraborty; J English; V Marks; M C Dumasia; D J Chapman
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

4.  A controlled comparison of corticotropin and hydrocortisone in the treatment of severe proctocolitis.

Authors:  J Powell-Tuck; N A Buckell; J E Lennard-Jones
Journal:  Scand J Gastroenterol       Date:  1977       Impact factor: 2.423

5.  Prednisolone absorption in acute colitis.

Authors:  P R Elliott; J Powell-Tuck; P E Gillespie; J M Laidlow; J E Lennard-Jones; J English; J Chakraborty; V Marks
Journal:  Gut       Date:  1980-01       Impact factor: 23.059

  5 in total
  7 in total

1.  Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis.

Authors:  Han Ho Jeon; Hyun Jung Lee; Hui Won Jang; Jin Young Yoon; Yoon Suk Jung; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim; Jae Hee Cheon
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

2.  Treatment with rhDNase in patients with cystic fibrosis alters in-vitro CHIT-1 activity of isolated leucocytes.

Authors:  M Weckmann; C Schultheiss; A Hollaender; I Bobis; J Rupp; M V Kopp
Journal:  Clin Exp Immunol       Date:  2016-07-28       Impact factor: 4.330

Review 3.  Medical treatment of ulcerative colitis.

Authors:  J E Lennard-Jones
Journal:  Postgrad Med J       Date:  1984-11       Impact factor: 2.401

Review 4.  Toward optimal use of corticosteroids in ulcerative colitis and Crohn's disease.

Authors:  J E Lennard-Jones
Journal:  Gut       Date:  1983-03       Impact factor: 23.059

5.  Management of severe ulcerative colitis.

Authors:  Neeraj Narula; Bindia Jharap; Jean-Frederic Colombel
Journal:  Curr Treat Options Gastroenterol       Date:  2015-03

Review 6.  Severe ulcerative colitis: at what point should we define resistance to steroids?

Authors:  Maria Esteve; Javier P Gisbert
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

7.  Management of severe acute colitis in district hospitals.

Authors:  J K Ritchie; S M Ritchie; P B McIntyre; C G Marks
Journal:  J R Soc Med       Date:  1984-06       Impact factor: 18.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.